TScan Therapeutics (TCRX)

• Market cap: $48.6M
• 1 day: -1.68%
• 5 days: -8.1%
• 1 month: -24.19%
• 3 months: -35.95%
• 6 months: -27.16%
• Year to date: -27.16%
• 1 year: -57.3%
• 5 years: -92.57%
• 10 years: -92.92%
• Sector: Healthcare
• Industry: Biotechnology

About: TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Employees: 142